TrademarkDir
CME DIRECT
DEAD

Serial Number

76327265

Owner

ADVP MANAGEMENT, L.P.

Attorney

John E. Ottaviani

First Use Date

Oct 26, 2001

Filing Date

Oct 19, 2001

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

CME DIRECT Trademark

Serial Number: 76327265 • Registration: 2703169

CME DIRECT is a trademark filed by ADVP MANAGEMENT, L.P. on October 19, 2001. The trademark is classified under Class 41 (Education & Entertainment). The application is currently no longer active.

Owner Contact Info

ADVP MANAGEMENT, L.P. (24 trademarks)

SUITE 1600
IRVING, TX 75039

Entity Type: 13

Trademark Details

Filing Date

October 19, 2001

Registration Date

April 1, 2003

First Use Anywhere

October 26, 2001

First Use in Commerce

October 26, 2001

Published for Opposition

June 11, 2002

Cancellation Date

November 7, 2009

Goods & Services

EDUCATIONAL SERVICES, NAMELY PROVIDING AN INTERACTIVE COURSE OF INSTRUCTION IN THE HEALTHCARE, MEDICAL AND PHARMACEUTICAL FIELD FOR PHYSICIANS AND OTHER HEALTH CARE PROFESSIONALS VIA A GLOBAL COMPUTER NETWORK

Filing History

CANCELLED SEC. 8 (6-YR)
Nov 7, 2009 C8..
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 14, 2009 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 14, 2009 REAP
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jan 14, 2009 ASCK
CASE FILE IN TICRS
May 29, 2008 CFIT
REGISTERED-PRINCIPAL REGISTER
Apr 1, 2003 R.PR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Feb 6, 2003 CNPR
ASSIGNED TO EXAMINER
Feb 5, 2003 DOCK
STATEMENT OF USE PROCESSING COMPLETE
Feb 3, 2003 SUPC
USE AMENDMENT FILED
Dec 5, 2002 IUAF
PAPER RECEIVED
Dec 5, 2002 MAIL
NOA MAILED - SOU REQUIRED FROM APPLICANT
Sep 3, 2002 NOAM
PUBLISHED FOR OPPOSITION
Jun 11, 2002 PUBO
NOTICE OF PUBLICATION
May 22, 2002 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 7, 2002 CNSA
EXAMINERS AMENDMENT MAILED
Feb 28, 2002 CNEA
NON-FINAL ACTION MAILED
Jan 28, 2002 CNRT
ASSIGNED TO EXAMINER
Jan 10, 2002 DOCK

Related Trademarks

More from this Owner

RX REVIEW

RX REVIEW

RX REVIEW

RX REVIEW

RX REVIEW

RX REVIEW

ADVANCERX

ADVANCERX

ADVANCERX

ADVANCERX

ADVANCERX

ADVANCERX